Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Using Biomarkers to Optimize Antibiotic Strategies in Sepsis

A legfontosabb adatok

Ki végzi
University of Pennsylvania
Hol
Philadelphia (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
145 fő vett részt
Kezdés
2012. jan.
Befejezés
2023. dec.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • Biomarker Algorithm Intervention
A regiszteradat frissítve
2024. január 5.

Ki vehet részt

Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 9 feltétel megnézéseKevesebb

Ki vehet részt

  • SIRS Criteria; SIRS is considered to be present when patients have more than one of the following clinical findings:; body temperature >38°C or <36°C; heart rate >90 min-1; respiratory rate of >20 min-1 or a Paco2 of <32 mm Hg; and a white blood cell count of >12,000 cells µL-1 or <4,000 µL-1
  • new empiric antibiotic therapy is initiated, indicating the suspicion of infection. Accepted criteria for SIRS will be used for the Medical Intensive Care Unit and Surgical Intensive Care Unit populations, with appropriate age-specific vital signs definitions to help make the definitions relevant for the Pediatric Intensive Care Unit population

Ki nem vehet részt

  • absence of initiation or expansion of antibiotic therapy despite meeting criteria for sepsis
  • active chemotherapy within the 3 months preceding eligibility or
  • presence of an immunocompromising condition; An immunocompromising condition will be defined as one of the following:
  • diagnosis of cystic fibrosis; These criteria all represent conditions in which antibiotic use is much less likely to be decreased regardless of the results of a biomarker and are consistent with exclusion criteria used in past studies of the impact of biomarkers
  • human immunodeficiency virus (HIV) infection with a t-helper cell (CD4) count <200 cell/mm3; 2) immunosuppressive therapy after organ transplantation
  • neutropenia (<500 neutrophils/mm3)
  • a code status of "do not resuscitate"

Helyszínek itt: Egyesült Államok

  • Hospital of the University of Pennsylvania - Medical Intensive Care UnitPhiladelphia, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The proposed work will provide critical insights into the potential impact of a biomarker-based algorithm on reducing unnecessary antibiotic use in different adult and pediatric/neonatal ICU's. This proposal will also assess the costs (or savings) of a biomarker-based intervention. Overall, the results of this work will be critical in informing future strategies to eliminate unnecessary antibiotic use and curb the continued rise in antimicrobial resistance.

A vizsgálat 2 csoportja

  • ObservationalNincs vizsgálati kezelés, összehasonlításként

    9 blood biomarkers (including C reactive protein and Procalcitonin) will be assessed across 3 days. Results will not be shared with the subject's medical team. At 3 days, the definitive diagnosis of infection will be determined using Center for Disease Control (CDC) criteria; this will serve as the gold standard for determining biomarker test characteristics. Additional data to collect: demographics, comorbidities, medication use (like antibiotics), lab cultures, x-rays, sepsis resolution, length of hospital stay, and ultimate outcome (i.e., discharge, death). Phase I will identify the biomarker(s) providing the greatest negative predictive value in identifying patients at very low likelihood bacterial infection.

  • Biomarker Algorithm InterventionA vizsgált kezelés

    The Algorithm arm is equivalent to the intervention. Biomarker algorithm along with the patient's biomarker assay results will be given to clinical team to assist in deciding to continue antibiotics. The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network - Randomized Control Trial
A regiszteradat frissítve
2024. január 5.